Introduction: Family history (FH) of Alzheimer's disease (AD) affects mitochondrial function and may modulate effects of translocase of the outer mitochondrial membrane 40 kDa (TOMM40) rs10524523 ('523) poly-T length on memory decline. Methods: For 912 nonapolipoprotein ε4 middle-aged adults and 365 aged adults across the AD spectrum, linear mixed models gauged FH and TOMM40 '523 interactions on memory and global cognition between baseline and up to 10 years later. A cerebrospinal fluid mitochondrial function biomarker was also assessed. Results: For FH negative participants, gene-dose preservation of memory and global cognition was seen for "very long" versus "short" carriers. For FH positive, an opposite gene-dose decline was seen for very long versus short carriers. Maternal FH was a stronger predictor in aged, but not middle-aged, participants. Similar gene-dose effects were seen for the mitochondrial biomarker aspartate aminotransferase. Discussion: These results may clarify conflicting findings on TOMM40 poly-T length and ADrelated decline.
Introduction
The apolipoprotein E (APOE) gene is the most replicated genetic risk factor for late-onset Alzheimer's disease (LOAD) [1] . Subjects without the ε4 allele (non-APOE 34s) are considered at neutral risk but show substantial variability for developing Alzheimer's disease (AD), where there is tremendous interest in finding genetic risk factors for non-APOE 34s that strongly predict memory, global decline, and cognitive impairment risk. As mitochondrial dysfunction is associated with LOAD [2] , several groups have investigated gene loci that impact mitochondrial bioenergetics, such as translocase of the outer mitochondrial membrane 40 kDa (TOMM40).
TOMM40 shares a strong linkage disequilibrium with APOE on chromosome 19 [3] . TOMM40 constitutes the central channel of the outer mitochondrial membrane, through which mitochondria-specific ribosomal preproteins enter for post-translational modification in the inner matrix [4] . Genome-wide association studies have implicated several TOMM40 single-nucleotide polymorphisms (SNPs) in increased LOAD risk, cognitive decline, and brain atrophy, particularly SNP rs2075650 that has consistently shown such associations [4] [5] [6] [7] . In addition, a TOMM40 variable length deoxythymidine-homopolymer (poly-T) at rs10524523 ('523) within intron 6 has sometimes been shown to associate with LOAD risk. Among non-APOE 34s, the phase-in haplotypes are APOE ε3-linked to either a TOMM40 '523 "short" (S) or "very long" (VL) poly-T length [8] . Some studies find that subjects with the VL allele have worse memory and executive function scores in middle-aged [6] and aged [9] cohorts. To date, several studies have also found that TOMM40 VL in non-APOE 34s or APOE ε3/ε4s predicts memory deficits or earlier age of AD onset [6, [8] [9] [10] [11] [12] . However, other reports with large samples have found no effect or a benefit of TOMM40 VL on age of onset and memory decline [13] [14] [15] .
It may be important to account for other factors that can modulate mitochondrial function, such as AD family history (FH). AD FH is typically defined as maternal or paternal LOAD onset between ages 65 and 80 [16] . Both FH and TOMM40 influence mitochondrial bioenergetic processes needed for adenosine triphosphate (ATP) synthesis. For example, maternal FH (FHM) is related to reduced cytochrome oxidase activity [17] , leading to electron transport chain dysfunction, lower ATP production, and neuronal damage. Like TOMM40, FH can increase AD risk independent of APOE [18] . To link FH and TOMM40 with AD, the mitochondrial cascade hypothesis posits that multiple factors determine baseline and age-related decline in mitochondrial function [19] . As neurons in hippocampus and other medial temporal lobe areas have high ATP requirements [16] , FH and TOMM40 might interact to affect mitochondrial dysfunction and contribute to memory and global cognitive decline, as well as cognitive impairment risk.
Our objective was to explore FH and TOMM40 interactions separately in non-APOE 34 late middle-aged or aged subjects from the Wisconsin Registry for Alzheimer's Prevention (WRAP) study or Alzheimer's Disease Neuroimaging Initiative (ADNI), respectively, to see if FH or FHM modulated TOMM40 effects in middle-age and along the AD spectrum in old age. The primary outcomes were longitudinal memory decline in both cohorts and global decline in the aged cohort. Previous WRAP and ADNI reports either focused on cross-sectional cognition with fewer subjects [6] or age of onset but not on cognitive or mitochondrial outcomes [13] .
To establish that FH and TOMM40 meaningfully interacted to affect mitochondrial processes, cerebrospinal fluid (CSF) levels of a cytosolic aspartate aminotransferase (AST) peptide were gauged. Cytosol AST is an enzyme that facilitates catabolism of glucogenic amino acids through the malate-aspartate shuttle by a final conversion step of aspartate to oxaloacetate, helping to maximize ATP production through glycolysis [20, 21] . AST, also called glutamic oxaloacetate transaminase, differs in CSF levels among AD patients and related dementias [22] , and shows higher concentrations in AD frontal and parietal cortices [23] . APOE 34 subjects were not considered for this report, as their in-phase TOMM40 genotype ("long", or L) is different and could confound effects of S and VL genotypes in APOE ε3/ε4 subjects.
Methods

Participants
Late middle-aged subjects (91.3% Caucasian, nonHispanic) were recruited from the WRAP study [24] . Participants were originally recruited from 40 to 65 years. There were 912 non-APOE 34 (129 APOE ε2/ε2 or ε2/ε3; 783 APOE ε3/ε3) participants with TOMM40 '523 and neuropsychological data. Cognitive performance was assessed once every roughly 2 years over four waves, from baseline to approximately 7 to 10 years later for a given participant.
Data on aged subjects (92.7% Caucasian, non-Hispanic) was obtained from the ADNI database (adni.loni.usc.edu). The primary goal of ADNI was to test whether serial magnetic resonance imaging, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. Among 365 non-APOE 34s (60 APOE ε2/ε2 or ε2/ε3; 305 APOE ε3/ε3), TOMM40 '523 data were available for 146 cognitively normal (CN), 163 MCI, and 56 AD participants. Data were downloaded from baseline and months 6, 12, 24, and 36. All subjects had (1) demographic measures, (2) TOMM40 '523 poly-T genotype, (3) APOE genotype, and (4) neuropsychological performance. We also examined clinical diagnosis at baseline and month 36.
AD family history
For WRAP, a parental history of AD-defined by clinical diagnosis or autopsy before ages 70 and 75 years for paternal FH and FHM, respectively-was determined as described [25] . For ADNI, the presence of FHM and paternal FH was determined for AD by the participant, informant, or both.
Protocol approvals, registrations, and patient consents
For WRAP, the University of Wisconsin-Madison Health Sciences Institutional Review Board approved the study, and all participants provided written informed consent. For ADNI, written informed consent was obtained from all ADNI participants at their respective ADNI sites. Sitespecific Institutional Review Boards approved the ADNI protocol.
APOE genotyping
For ADNI, the Biomarker Core at the University of Pennsylvania conducted APOE genotyping [26] as described in white papers (http://adni.loni.usc.edu/). For WRAP, extraction and isoform classification of APOE alleles have been described previously [6] . Participants who were non-APOE 34 were analyzed. Ancillary analyses were also conducted on APOE 33/33 carriers only or APOE 32 carriers (Supplementary Text 1) , where the pattern of results was similar for APOE 33/33 subjects.
TOMM40 genotyping
For both WRAP [6] and ADNI [8, 11] , genotyping of TOMM40 '523 poly-T was conducted as described (Polymorphic DNA Technologies, Inc, Alameda, CA) [6] . Briefly, the '523 poly-T polymorphism was determined using polymerase chain reaction amplification of each region's variant site, followed by corresponding A-peaks to the N values (poly-T length) of each component, relative to the C-peak reference base upstream of the poly-T intron site. Manual electrogram review was also conducted to avoid errors. This process obviated the concern of polymerase chain reaction slippage.
Cognition, clinical, and mitochondrial biomarker measures
For WRAP, participants underwent a full neuropsychological battery. Although factor analysis derived six cognitive factors [27, 28] , the focus of this report is on memory-to maintain overlap with ADNI data and reduce type 1 error. Latent memory factors were derived as described in ref [27] , which encapsulated immediate and delayed memory. Composite scores based on the latent factor structure were largely derived from Z-scores of longitudinal measures of the immediate memory and delayed recall portions of the Rey Auditory Verbal Learning Test (RAVLT) [29] . RAVLT subcomponents were not considered because they have been investigated elsewhere [6] .
For ADNI, as described in ref [30] , a Z-score general memory composite was derived from longitudinal immediate and delayed RAVLT scores, AD Assessment ScheduleCognition [31] , Mini-Mental State Examination (MMSE), and the Wechsler Memory Scale-Revised Logical Memory II. Total RAVLT scores for immediate memory and delayed recall were separately assessed to establish which aspect of memory function drove the factor result. Global cognition and function were assessed by MMSE and Clinical Dementia Rating-sum of boxes (CDR-sob). Finally, as described in ref [32] , a peptide of CSF cytosol AST (IVASTLSNPEL-FEEWTGNVK) was available in 119 ADNI subjects only at baseline, as acquired by the ADNI Biomarker Core using mass spectrometry [32] . No other direct mitochondrial biomarkers were present in existing assays. Values are in arbitrary log units derived from signal intensity.
Statistical analysis
SPSS 23 (Chicago, IL) was used for analyses. Data were analyzed using mixed-effects regression models. Model equations and both fixed and random terms are described in Supplementary Text 2. Aikake's Information Criterion was used to determine the optimal covariance matrix. In each cohort separately (WRAP or ADNI), for a given Zscore memory factor, we tested all main effects and interactions for FH, TOMM40, and Time as predictors in a single model. A similar approach was used for testing global cognition outcomes in ADNI participants. This approach assessed if FH modified TOMM40 genotype associations, and if these effects on memory decline were the same over time or dynamically changed based on FH and genotype. To explore which memory components drove significant findings for the single ADNI memory factor, immediate and delayed RAVLT scores were assessed. Exploratory analyses were also conducted with FHM, due to FHM's influence on mitochondrial function [17] . We controlled for sex, age, and education. A similar mixed model approach was used to predict baseline CSF AST in ADNI. Logistic regression was used in ADNI data to identify if FH and TOMM40 predicted a greater likelihood of being MCI or AD at baseline versus the CN reference group. Importantly, we did not investigate if TOMM40 and FH modified clinical diagnosis effects on memory because of small sample sizes among subgroups stratified by TOMM40, FH, and APOE.
To minimize type 1 error, as described elsewhere [25] , Holm-Bonferroni correction was used to maintain a familywise error rate of P , .05. Briefly, for WRAP, familywise adjusted P values were .025 and .05 for testing 1 model between two latent memory factors, and similarly .025 and .05 for ADNI MMSE and CDR-sob. If a TOMM40*FH or TOMM40*FH*Time interaction was not significant, we separately examined two additional models in FH2 and FH1 to tests main effects of TOMM40 and its interaction with Time. This required familywise adjustment of .017, .025, and .050 to yield significance. This approach is more optimal than conventional Bonferroni correction [33] [34] [35] . No statistical violations were found for collinearity, normality, outliers, or model overfitting.
Results
Data summary
Participant data for 912 WRAP and 365 ADNI non-APOE 34 participants are listed in Table 1 . For WRAP, the sample size was 333 FH2 (S/S 5 112; S/VL 5 143; and VL/VL 5 78) versus 579 FH1 (S/S 5 177; S/VL 5 285; and VL/VL 5 117). For ADNI, the sample size was 238 FH2 (S/S 5 59; S/VL 5 124; and VL/VL 5 55) versus 127 FH1 (S/S 5 28; S/VL 5 71; and VL/VL 5 28). The roughly 1:2:1 ratio among genotypes is comparable to what has been reported in predominantly Caucasian cohorts [6, 8] . All latent factor analyses without APOE 32s remained significant (Supplementary Text 1).
WRAP: TOMM40 and FH interaction effects on memory performance over 7 to 10 years
We first examined change in immediate and delayed memory factors in late middle-aged APOE 342 WRAP subjects. For immediate memory, a TOMM40*FH effect (F 5 4.704, estimate 6 standard error [SE] 5 20.279 6 0.192, P 5 .009) showed that TOMM40 VL was related to better memory among FH2 and worse memory among FH1 subjects, regardless of Time ( Supplementary Fig. 1 ). For example, higher scores were seen in FH2 VL/VL versus S/S (D Cohen 5 0.352) and lower scores for FH1 VL/VL versus S/S (D Cohen 5 20.787). It should be noted here and throughout the report that FH also modified S/S genotype effects. When exploring FHM, a FHM*TOMM40 interaction (F 5 2.935, estimate 6 SE 5 20.320 6 0.248, P 5 .050) showed similar effects.
For the delayed memory factor, a TOMM40*FH*Time interaction (F 5 3.695, estimate 6 SE 5 0.502 6 0.189, 
ADNI: TOMM40 and FH interactions for MCI and AD diagnosis odds ratios
For FH and TOMM40, no main effects or interactions for risk of MCI or AD versus CN diagnosis were noted. In exploratory analyses for FHM, a TOMM40*FHM interaction (Wald 5 6.154, P 5 .046) showed that for FHM2, S/S and S/VL compared with VL/VL participants had a 4.67 higher odds ratio of being MCI or AD at baseline, whereas for FHM1 the S/S and S/VL genotypes had a 0.215 lower odds ratio. As there were only 102 non-APOE 34 MCI converters to AD by month 36, there was not sufficient sample size to stratify by FH and TOMM40 to conduct age of onset or logistic regression analyses for stable versus progressive MCI. 
ADNI: TOMM40 and FH interactions on memory performance over 3 years
Unlike WRAP, the TOMM40*FH*Time interaction was nonsignificant among ADNI participants, perhaps because of lower power. When stratified by FH status, FH2 subjects showed a TOMM40*Time effect (F 5 2.465, estimate 6 SE 5 20.349 6 0.096, P 5 .012), whereas FH1 subjects had a TOMM40 main effect (F 5 3.453, estimate 6 SE 5 0.228 6 0.070, P 5 .008). FH2 TOMM40 genotypes did not vary at baseline, whereas 3 years later S/S carriers showed a decline of more than 0.3 standard deviations, with no decline evident in S/VL or VL/VL (D Korr 5 0.497). FH1 TOMM40 VL/VL carriers, meanwhile, showed a gene-dose decrease in memory performance relative to S/S or S/VL that did not vary over time (D Cohen 5 0.430).
Analyses with FHM had similar, stronger effects. FHM2 showed a TOMM40*Time effect (F 5 2.352, estimate6SE 5 20.318 6 0.094, P 5 .017), where, for example, S/S but not VL/VL carriers evinced decline (D Korr 5 0.378) (Fig. 3, left panels) . Among FHM1, a main effect of TOMM40 (F 5 4.284, estimate 6 SE 5 0.350 6 0.139, P 5.014) illustrated a clear gene-dose effect on overall memory performance that did not change for more than 3 years (Fig. 3, right panel) . For example, VL/VL versus S/S carriers had lower memory scores (D Cohen 5 0.607).
ADNI: TOMM40 and FH interaction effects on RAVLT over 3 years
As ADNI has one memory factor including immediate and delayed components, we did follow-up analyses to see if the RAVLT encoding or retention portions explained results for the factor. For RAVLT immediate memory (i.e., trials 1-5 total), a TOMM40*FH*Time (F 5 2.203, estimate 6 SE 5 9.124 6 2.942, P 5 .027) pattern similar to the general memory factor emerged. VLs of both FH For FHM, a similar TOMM40*FHM*Time interaction (F 5 2.008, estimate 6 SE 5 8.412 6 3.558, P 5 .042) showed no FHM differences at baseline, but VL gene-dose preservation (FH2) or decline (FH1) over 3 years ( Supplementary Fig. 2 ). For example, FH2 VL/VL versus S/S had progressively better scores (D Korr 5 0.601) but FH1 VL/VL versus S/S had progressively worse scores (D Korr 5 0.271).
RAVLT delayed memory was not affected by FH or FHM, TOMM40, or their interaction with or without Time. These results suggest that immediate verbal memory encoding rather than delayed retention may underlie the statistical effect on the ADNI memory factor.
ADNI: TOMM40 and FH effects on global decline over 3 years
For CDR-sob, no effects were significant when considering FH. For FHM, a TOMM40*FHM*Time interaction (F 5 2.187, estimate 6 SE 5 2.854 6 0.961, P 5 .025) showed that global decline varied among TOMM40 groups based on FHM status. For FHM2, a marginally lower CDR-sob at baseline was seen between VL/VL versus S/S, where by 3 years later S/VL and VL/VL genotypes showed less decline compared with S/S (D Korr 5 0.286) (Fig. 4, left  panel) . In contrast, FHM1 VL/VL carriers did not differ at baseline from S/S, but showed more progressive decline after 3 years (D Korr 5 20.337) (Fig. 4, right panel) .
For MMSE, a TOMM40*FH*Time effect (F 5 1.960, estimate 6 SE 5 1.179 6 0.662, P 5 .048) revealed a weak pattern similar to CDR-sob. For instance, FH2 VL/ VL versus S/S subjects showed less progressive decline (D Korr 5 0.1). However, FH 1 VL/VL did not differ from S/S at baseline or over the course of 3 years. For FHM, a similar TOMM40*FHM*Time interaction (F 5 2.452, estimate 6 SE 5 1.091 6 0.660, P 5 .012) showed that VL/VL versus S/S carriers had marginally higher MMSE scores at baseline, where 3 years later the S/S genotype showed greater decline compared with S/VL or VL/VL (D Korr 5 0.125) ( Supplementary Fig. 3, left panel) . FHM1 participants did not differ at baseline or up to 3 years later ( Supplementary Fig. 3, right panel) .
Discussion
In this report, we found in middle-aged and aged cohorts that FH altered TOMM40 '523 poly-T genotype associations on memory, and additionally in aged participants for both global decline and cognitive impairment risk. Specifically, VL genotype was related to ameliorative (FH2) or deleterious (FH1) effects on memory factors, RAVLT immediate memory, CDR-sob, and MMSE scores. FHM had stronger effects relative to FH in the old age cohort. Fig. 3 . FH and TOMM40 '523 effects on memory decline in old age. For the aged ADNI cohort, maternal FH (FHM) status modulates the effect of TOMM40 '523 very long (VL) carriage on general memory performance. TOMM40 '523 genotypes showed relative changes in memory decline for FHM negative participants over time, whereas FHM positive participants showed gene-dose differences that remained constant from baseline to month 36. ***P , .001 for genotype differences relative to other genotypes at a given time point. Data are presented as the mean 6 standard deviation. Abbreviations: ADNI, Alzheimer's Disease Neuroimaging Initiative; APOE 34, apolipoprotein ε4; FH, family history; Mo., month; S, short; TOMM40, translocase of the outer mitochondrial membrane 40 kDa.
FH and TOMM40 interact to affect memory decline in late middle-age
Within WRAP, Johnson et al. [6] originally found genedose associations (S/S, S/VL, VL/VL) with worse RAVLT total recall and retrieval from primacy, where S/S versus VL/VL subjects showed differences of over half a standard deviation (Cohen's D 5 0.599 to 0.718). Comparatively, by 7 to 10 years later, we found for the delayed memory factor that FH2 S/S and VL/VL differed by a Cohen's D 5 1.126, where for FH1 that difference was Cohen's D 5 21.322. These findings were stronger than that for the immediate memory factor, perhaps because delayed memory is a more sensitive cognitive feature for detecting decline related to AD [36] . Caselli et al. [10] noted that non-APOE 34 S/S versus VL/VL subjects showed less RAVLT decline in middle-age, but a flat slope after age 60 years, indicating that initial differences in cognitive performance abated over time. Yet, in this report, VL/VL homozygotes differed from other genotypes at baseline (mean age 5 54.20) and showed less (FH2) or more (FH1) decline by the last available study visit (mean age 5 63.21).
FH and TOMM40 interact to affect memory decline in old age
FH and TOMM40 poly-T genotype showed similar effects in ADNI. Effects were stronger in FHM than FH, which may be because of age-related mitochondrial dysfunction [37] . Unlike WRAP, TOMM40 VL effects between FH2 and FH1 groups were similar at baseline, but over time showed progressive gene-dose differences in memory and global decline. These results may explain the null ADNI findings of Jun et al. [14] , and in particular Cruchaga et al. [13] noting later age of onset among APOE ε3 homozygotes with VL carriage. Indeed, given the opposing effects we see for FH2 and FH1 in ADNI, TOMM40 VL effects would largely cancel out when collapsed across FH status. Hayden et al. [9] also found a mild but significant gene-dose response (S/S, S/VL, VL/VL) for improved global function. Comparably, we found that FH2 VL carriers showed less decline in CDR-sob and MMSE scores.
FH and TOMM40 affect mitochondrial function in old age
Importantly, among a subset of ADNI subjects, FH modified VL carriage associations of CSF AST, a biomarker of mitochondrial function [20, 21] that is higher in AD CSF [22] and cortical tissue [23] . As glucose metabolism decreases in AD, alternative sources of energy are used to sustain energy-intensive synaptic processes. Cytosolic AST may through the malate-aspartate cycle maximize ATP production [21] , as well as maintain ATP and antioxidative capacity in neural cells [38] .
Limitations and future work
There are serious limitations that should be addressed. First, the sample size for some subgroups in ADNI was small, particularly for FH1 and FHM1 subjects, which may explain nonsignificant trends related to decline. We intend to re-examine these effects in additional AD cohorts. Nonetheless, we consistently found that for FH2, VL carriage was associated with lower AD risk, less mitochondrial dysfunction via the CSF biomarker AST, and less memory and global decline over time, whereas the opposite pattern was seen for FH1. Although FH and TOMM40 may affect mitochondrial function, it is not clear if FH is modulating TOMM40 function by epigenetic, environmental, or other factors. It is clear that FHM affects cytochrome oxidase [17] production that impacts AD progression, and that SNPs for several mitochondrial genes contribute to a higher odds ratio for AD [39] in ADNI. Although FH in WRAP and ADNI both modified TOMM40 poly-T effects, FHM exerted modest effects in middle age but more potent associations in the aged cohort. Mitochondrial dysfunction is thought to increase with age [37] , where the influence of FHM on mitochondrial bioenergetics may only be present in older subjects evincing damage because of reactive oxygen species. Despite these limitations, this report may clarify why the TOMM40 '523 literature has shown beneficial, null, and/ or detrimental effects. We propose that the proportion of participants with FH1 may influence TOMM40 '523 effects on memory, age of onset, and other outcomes. Our future work will investigate additional mitochondrial biomarkers and examine impact on neural, CSF biomarker, and metabolic outcomes. 
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RESEARCH IN CONTEXT
1. Systematic review: We searched for articles in PubMed using the keywords: translocase of outer mitochondrial membrane 40; Alzheimer's disease; mitochondrial function, aspartate aminotransferase; memory; preclinical AD; poly-T; rs10524523. We focused on human work to examine translocase of the outer mitochondrial membrane 40 kDa (TOMM40) '523 genotype and effects on memory decline and Alzheimer's disease (AD) risk.
2. Interpretation: This is the first human study to demonstrate that AD family history modifies the effect of TOMM40 '523 genotype on memory, global cognition, and a biomarker of mitochondrial function. Findings were similar across two separate cohorts of cognitively normal middle-aged and aged subjects across the AD spectrum. Varying proportions of AD family history in subjects may explain mixed findings in the TOMM40 '523 literature.
3. Future directions: Data from other observational AD cohorts will be collected to confirm results. Higher sample size will allow AD age of onset and mild cognitive impairment conversion risk analyses. Effects on neural, metabolic, and biomarker outcomes will be assessed.
